Bob Martin Clear Wormer 100 mg Film Coated Tablets for Small Dogs and Puppies

البلد: أيرلندا

اللغة: الإنجليزية

المصدر: HPRA (Health Products Regulatory Authority)

العنصر النشط:

Nitroscanate

متاح من:

The Bob Martin Company

ATC رمز:

QP52AX01

INN (الاسم الدولي):

Nitroscanate

جرعة:

100 mg/tablet

الشكل الصيدلاني:

Coated tablet

نوع الوصفة الطبية :

CAM: Companion Animal Medicine as defined in relevant national legislation

المجموعة العلاجية:

Dogs

المجال العلاجي:

nitroscanate

الخصائص العلاجية:

Endoparasiticide

الوضع إذن:

Authorised

تاريخ الترخيص:

1995-07-10

خصائص المنتج

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Bob Martin Clear Wormer 100 mg Film Coated Tablets for Small Dogs &
Puppies
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Film coated tablet.
Yellow film coated round convex tablet.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
The product is a broad spectrum anthelmintic for use in puppies and
adult dogs for the treatment of infection by adult
intestinal nematodes or cestodes of the following species:
Nematodes:_ Toxocara caninum, Toxascaris leonina, Ancylostoma caninum,
Uncinaria stenocephala_
Cestodes:_ Taenia hydatigena, Taenia pisiformis, Dipylidium caninum_
4.3 CONTRAINDICATIONS
Do not administer to sick or convalescing animals.
Do not use in puppies of less than 3 weeks of age.
Do not use in cases of hepatic dysfunction.
Do not use in cases of known hypersensitivity to the active substance.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
The product is not indicated for the treatment of_ Trichuris vulpis_
and gives only a limited level of control of
_Echinococcus granulosus._
Since the most common tapeworm of the dog (_Dipylidium caninum_) is
transmitted by a flea and has a very short pre-
patent period, it is important to pay attention to flea control to
reduce the incidence of tapeworm in your pet.
Each tablet contains:
Nitroscanate
100 mg
For a full list of excipients, see section 6.1
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_